E P Prudius

Rostov Regional Clinical Hospital, Rostov-on-Don, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does E P Prudius research?

E P Prudius studies how well Revelise works for people who have suffered from ischemic strokes, which occur when blood flow to the brain is blocked. Their most significant research involves tracking the outcomes of patients treated with this medication in various real-life settings. Prudius is particularly interested in older adults and those with existing health complications, as these groups often face more challenges during recovery. The goal is to understand not just whether Revelise works, but how it can improve life quality after a stroke.

Key findings

  • In a study with 2,202 patients, 49.9% had good outcomes when discharged after treatment with Revelise.
  • This percentage increased to 66.4% after 90 days, indicating long-term benefits from the therapy.
  • The findings suggest that Revelise can significantly reduce stroke-related disabilities, even in older patients.

Frequently asked questions

Does Dr. Prudius study stroke treatments?
Yes, Dr. Prudius specifically studies treatments for ischemic strokes using Revelise (alteplase).
What outcomes does Dr. Prudius focus on in stroke patients?
Dr. Prudius focuses on the percentage of patients who experience positive outcomes after treatment, particularly improvement in their ability to function after a stroke.
Is Dr. Prudius's work relevant to older adults who have had strokes?
Yes, Dr. Prudius's research highlights how Revelise can benefit older adults, showing substantial recovery rates even among those with health issues.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.